临床实践中乌帕替尼治疗重度特应性皮炎：短期疗效和安全性结果 - Suppr

Treatment of Severe Atopic Dermatitis With Upadacitinib in Clinical Practice: Short-Term Efficacy and Safety Results.

作者信息

Pereyra-Rodriguez J J, Herranz P, Figueras-Nart I, Perez B, Elosua M, Munera-Campos C, Melgosa-Ramos J, Zaragoza V, Silvestre J F, Campos-Domínguez M, Guilabert A, Miquel J, Alcantara-Luna S, Serra-Baldrich E, Armario-Hita J C

机构信息

Department of Dermatology, University Hospital Virgen del Rocío, Sevilla, Spain.

Department of Dermatology, University Hospital La Paz, Madrid, Spain.

出版信息

J Investig Allergol Clin Immunol. 2023 Jun 15;33(3):211-213. doi: 10.18176/jiaci.0831. Epub 2022 Jun 7.

DOI:10.18176/jiaci.0831

PMID:35671128

Abstract

摘要

相似文献

Treatment of Severe Atopic Dermatitis With Upadacitinib in Clinical Practice: Short-Term Efficacy and Safety Results.临床实践中乌帕替尼治疗重度特应性皮炎：短期疗效和安全性结果

J Investig Allergol Clin Immunol. 2023 Jun 15;33(3):211-213. doi: 10.18176/jiaci.0831. Epub 2022 Jun 7.

Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials.度普利尤单抗治疗中重度特应性皮炎的疗效和安全性：来自两项随机临床试验 MEASURE UP 1 和 MEASURE UP 2 的随访数据分析。

JAMA Dermatol. 2022 Apr 1;158(4):404-413. doi: 10.1001/jamadermatol.2022.0029.

A real-world Australian experience of upadacitinib for the treatment of severe atopic dermatitis.澳大利亚真实世界中使用乌帕替尼治疗重度特应性皮炎的经验。

Australas J Dermatol. 2023 Nov;64(4):e352-e356. doi: 10.1111/ajd.14139. Epub 2023 Jul 31.

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.度普利尤单抗联合局部皮质类固醇治疗青少年和成人中重度特应性皮炎（AD Up）的安全性和有效性：一项随机、双盲、安慰剂对照、3 期临床试验的结果。

Lancet. 2021 Jun 5;397(10290):2169-2181. doi: 10.1016/S0140-6736(21)00589-4. Epub 2021 May 21.

Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis.阿巴西普、巴瑞替尼和乌帕替尼治疗中重度特应性皮炎的疗效和安全性比较：一项网络荟萃分析。

Dermatol Ther. 2022 Sep;35(9):e15636. doi: 10.1111/dth.15636. Epub 2022 Jul 27.

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.每日一次乌帕替尼对比安慰剂治疗中重度特应性皮炎青少年和成人患者（Measure Up1 和 Measure Up2）：两项复制性、双盲、随机对照 3 期临床试验结果。

Lancet. 2021 Jun 5;397(10290):2151-2168. doi: 10.1016/S0140-6736(21)00588-2. Epub 2021 May 21.

Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results.乌帕替尼加局部皮质类固醇治疗特应性皮炎：第 52 周 AD Up 研究结果。

J Allergy Clin Immunol. 2022 Mar;149(3):977-987.e14. doi: 10.1016/j.jaci.2021.07.036. Epub 2021 Aug 14.

Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib.选择性 JAK1 抑制剂治疗特应性皮炎：聚焦乌帕替尼和阿布昔替尼。

Am J Clin Dermatol. 2020 Dec;21(6):783-798. doi: 10.1007/s40257-020-00548-6.

Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.乌帕替尼治疗中重度特应性皮炎成人患者：一项随机、安慰剂对照试验的 16 周结果。

J Allergy Clin Immunol. 2020 Mar;145(3):877-884. doi: 10.1016/j.jaci.2019.11.025. Epub 2019 Nov 29.

Upadacitinib for moderate to severe atopic dermatitis.巴瑞替尼治疗中重度特应性皮炎。

Immunotherapy. 2023 Aug;15(11):799-808. doi: 10.2217/imt-2023-0037. Epub 2023 May 17.

引用本文的文献

Atypical tinea corporis with Id reaction: A case report and successful treatment with upadacitinib.伴有Id反应的非典型体癣：一例报告及乌帕替尼成功治疗

IDCases. 2025 Jun 21;41:e02300. doi: 10.1016/j.idcr.2025.e02300. eCollection 2025.

Effectiveness and Safety of Upadacitinib for Adolescents with Atopic Dermatitis in a Real-World Setting.在真实环境中乌帕替尼治疗青少年特应性皮炎的疗效和安全性。

Clin Drug Investig. 2024 Aug;44(8):629-634. doi: 10.1007/s40261-024-01382-y. Epub 2024 Jul 16.

Real-world effectiveness and safety of Janus kinase 1 inhibitors for the treatment of moderate-to-severe atopic dermatitis: a single-center, prospective study in China.用于治疗中重度特应性皮炎的Janus激酶1抑制剂的真实世界有效性和安全性：中国一项单中心前瞻性研究。

Front Med. 2024 Aug;18(4):752-756. doi: 10.1007/s11684-024-1063-9. Epub 2024 Jul 16.

Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review.乌帕替尼在重度特应性皮炎患者真实世界中的实际应用：一项系统评价

Clin Cosmet Investig Dermatol. 2024 Mar 12;17:593-604. doi: 10.2147/CCID.S329442. eCollection 2024.

Drug Survival of Upadacitinib and Predicting Factors of Discontinuation in Adult Patients Affected by Moderate-to-Severe Atopic Dermatitis: An Italian Multicenter Analysis.乌帕替尼在中重度特应性皮炎成年患者中的药物留存率及停药预测因素：一项意大利多中心分析

J Clin Med. 2024 Jan 18;13(2):553. doi: 10.3390/jcm13020553.

Optimal Use of Jak Inhibitors and Biologics for Atopic Dermatitis on the Basis of the Current Evidence.基于当前证据的特应性皮炎中JAK抑制剂和生物制剂的最佳应用

JID Innov. 2023 Feb 24;3(3):100195. doi: 10.1016/j.xjidi.2023.100195. eCollection 2023 May.

Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry.乌帕替尼治疗特应性皮炎患者的疗效，包括对度普利尤单抗和/或巴瑞替尼应答不足的患者：来自 BioDay 登记研究的结果。

Acta Derm Venereol. 2023 Feb 16;103:adv00872. doi: 10.2340/actadv.v103.5243.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Treatment of Severe Atopic Dermatitis With Upadacitinib in Clinical Practice: Short-Term Efficacy and Safety Results.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献